Overview

Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:
0

Participant gender:
All

Summary

Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection. This study aims to better understand the potential of both hybrid and igh-dose dual therapies in the treatment of H. pylori infection. .

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chang Gung Memorial Hospital

Treatments:

Amoxicillin
Clarithromycin
Metronidazole
Rabeprazole

Criteria

Inclusion Criteria:

1. H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or
gastritis.

Exclusion Criteria:

1. Previous H. pylori-eradication therapy

2. ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks

3. patients with allergic history to the medications used

4. patients with previous gastric surgery

5. the coexistence of serious concomitant illness (for example, decompensated liver
cirrhosis, uremia)

6. pregnant women.